-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-510022-33-00
5
2024-10-03
HIV-1 infection
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2023-505678-14-00
4
2024-08-19
Ulcerative Colitis
-
2023-507555-29-00
9
2024-08-16
LA/mGC/GEJC (locally advanced unresectable or metastatic gastric cance
-
2023-509807-34-00
4
2024-08-12
Early Alzheimer’s Disease (Mild Cognitive Impairment and
Mild Dementi
-
2023-507129-40-00
4
2024-08-06
interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-504026-19-01
5
2024-06-05
Prostate Cancer
-
2022-502050-14-00
5
2024-06-04
Crohn's disease
-
2023-507528-21-00
5
2024-05-23
Gorlin Syndrome
-
2023-503545-67-00
5
2024-04-30
Tourette's Disorder
-
2023-503221-19-00
4
2024-04-18
Advanced Non-Small Cell Lung Cancer
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i
-
2023-505121-14-00
5
2024-01-18
Moderate to Severe Plaque Psoriasis
-
2023-503920-14-00
5
2024-01-02
Non-Small Cell Lung Cancer (NSCLC)
-
2022-502739-20-00
5
2023-11-16
Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis o
-
2024-511337-35-00
4
2023-11-16
The trial will include patients with so called "fusion-driven", metast
-
2022-501788-41-00
5
2023-11-14
Ulcerative Colitis
-
2022-502286-16-00
5
2023-10-27
Primary Generalized Tonic-Clonic Seizures